Regulators at the Federal Trade Commission last week announced they approved Pfizer Inc.'s agreement to license a portfolio of treatments for Alzheimer's disease and other conditions from Transtech Pharma Inc. Pfizer, the maker of Viagra, gains exclusive worldwide rights to the compounds, known as RAGE (receptor for advanced glycation end products) modulators. The agreement also calls for additional undisclosed milestones and sales royalties.
October 23, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Regulators at the Federal Trade Commission on Thursday announced they approved Pfizer Inc.’s agreement to license a portfolio of treatments for Alzheimer’s disease and other conditions from Transtech Pharma Inc.
The High Point, N.C., drug seller is set to receive $155 million in upfront and near-term payments.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
